Pooled allogenic fecal microbiotherapy MaaT013 for the treatment of steroid-refractory gastrointestinal acute graft-versus-host disease: results from the phase IIa HERACLES study and expanded access program - MaaT Pharma

Download the poster

Previous PostLabiotech - MaaT Pharma: leading the charge in microbiome therapeutics
Next PostPooling of faecal material results in standardized and high-richness microbiotherapy products MaaT013 and MaaT033

© 2025 MaaT Pharma. MaaT Pharma’s mission is to restore microbiome function to treat life-threatening diseases

MaaT Pharma dans les médias MaaT Pharma in the News Devenez membre du club Become a member of the club